A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10332659" target="_blank" >RIV/00064203:_____/16:10332659 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/16:10332659

Result on the web

<a href="http://dx.doi.org/10.1371/journal.pone.0162866" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0162866</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0162866" target="_blank" >10.1371/journal.pone.0162866</a>

Result language

angličtina

Original language name

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics

Original language description

Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/ or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/LM2015091" target="_blank" >LM2015091: National Center for Medical Genomic</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

PLoS ONE

ISSN

1932-6203

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

9

Country of publishing house

US - UNITED STATES

Number of pages

19

Pages from-to

—

UT code for WoS article

000383723700018

EID of the result in the Scopus database

2-s2.0-84992409620